BTA injections can treat infantile esotropia

Article

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia.

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia, claims a paper in the journal Eye.

The investigation, led by Dr J. Chen, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China, included 47 patients with infantile esotropia who were randomly divided into two groups. Group A included 23 cases treated with bilateral injection of 2.5–3.75 U BTA combined with sodium hyaluronate (SH). In group B 24 patients were administered the BTA solution with SH. All patients did not undergo electromyography and injections were evaluated two weeks, three months and six months postoperatively.

Both groups presented with good alignment six months after injections, with group A at 30.4% and group B at 37.5%. Complicated ptosis and vertical deviation were 2.2% vs 20.8% and 2.2% vs 2.1% in groups A and B, respectively.

BTA injections with or without SH produced similar results and demonstrated effectiveness and feasibility. However, BTA injections with SH relatively decrease the frequency of complicated ptosis.

The abstract can be read here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.